Lenvatinib
Sign in to save this workspacePrimary targets: FLT1_VEGFR1, FLT4_VEGFR3, KDR_VEGFR2, RET · FDA status: FDA Approved
Selectivity scorecard
KISS
97.74
Gini
0.726
CATDS
0.020
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Lenvatinib. Strongest target: RET at 98.8% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | RET | 98.8% | 1.2% |
| 2 | KDR_VEGFR2 | 98.1% | 1.9% |
| 3 | FLT4_VEGFR3 | 97.4% | 2.6% |
| 4 | TNIK | 97.2% | 2.8% |
| 5 | FLT1_VEGFR1 | 94.8% | 5.2% |
| 6 | DDR2 | 94.3% | 5.7% |
| 7 | LCK | 93.4% | 6.6% |
| 8 | DDR1 | 92.3% | 7.7% |
| 9 | RIPK3 | 90.6% | 9.4% |
| 10 | PDGFRA | 88.0% | 12.0% |
| 11 | P38A_MAPK14 | 87.1% | 12.9% |
| 12 | C_KIT | 86.3% | 13.7% |
| 13 | FGFR1 | 85.5% | 14.5% |
| 14 | FGFR2 | 85.4% | 14.6% |
| 15 | FMS | 84.9% | 15.1% |
| 16 | FGFR3 | 79.9% | 20.1% |
| 17 | FGFR4 | 79.3% | 20.7% |
| 18 | MINK_MINK1 | 79.2% | 20.8% |
| 19 | SLK_STK2 | 77.1% | 22.9% |
| 20 | LYN | 76.6% | 23.4% |
Selectivity landscape
Where Lenvatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Lenvatinib.
Atlas insights for Lenvatinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 1715.86 | |
| ALLOGRAFT_REJECTION | 5640.83 | |
| ANDROGEN_RESPONSE | 892.92 | |
| ANGIOGENESIS | 1087.59 | |
| APICAL_JUNCTION | 6205.35 | |
| APICAL_SURFACE | 512.49 | |
| APOPTOSIS | 4094.46 | |
| BILE_ACID_METABOLISM | 491.25 | |
| CHOLESTEROL_HOMEOSTASIS | 991.36 | |
| COAGULATION | 634.27 | |
| COMPLEMENT | 3180.23 | |
| DNA_REPAIR | 1071.19 | |
| E2F_TARGETS | 2165.37 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 1095.37 | |
| ESTROGEN_RESPONSE_EARLY | 1700.62 | |
| ESTROGEN_RESPONSE_LATE | 1653.26 | |
| FATTY_ACID_METABOLISM | 730.70 | |
| G2M_CHECKPOINT | 2325.56 | |
| GLYCOLYSIS | 1857.58 | |
| HEDGEHOG_SIGNALING | 412.89 | |
| HEME_METABOLISM | 1143.22 | |
| HYPOXIA | 2548.12 | |
| IL2_STAT5_SIGNALING | 1799.88 | |
| IL6_JAK_STAT3_SIGNALING | 3342.20 | |
| INFLAMMATORY_RESPONSE | 2555.02 | |
| INTERFERON_ALPHA_RESPONSE | 516.22 | |
| INTERFERON_GAMMA_RESPONSE | 3984.78 | |
| KRAS_SIGNALING_DN | 382.24 | |
| KRAS_SIGNALING_UP | 2313.42 | |
| MITOTIC_SPINDLE | 3976.93 | |
| MTORC1_SIGNALING | 2184.63 | |
| MYC_TARGETS_V1 | 1990.77 | |
| MYC_TARGETS_V2 | 376.04 | |
| MYOGENESIS | 1542.98 | |
| NOTCH_SIGNALING | 177.74 | |
| OXIDATIVE_PHOSPHORYLATION | 1250.71 | |
| P53_PATHWAY | 2227.57 | |
| PANCREAS_BETA_CELLS | 168.99 | |
| PEROXISOME | 729.25 | |
| PI3K_AKT_MTOR_SIGNALING | 6045.40 | |
| PROTEIN_SECRETION | 1325.26 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 329.55 | |
| SPERMATOGENESIS | 625.67 | |
| TGF_BETA_SIGNALING | 1208.19 | |
| TNFA_SIGNALING_VIA_NFKB | 2281.59 | |
| UNFOLDED_PROTEIN_RESPONSE | 695.40 | |
| UV_RESPONSE_DN | 2823.42 | |
| UV_RESPONSE_UP | 2032.68 | |
| WNT_BETA_CATENIN_SIGNALING | 1085.78 | |
| XENOBIOTIC_METABOLISM | 1173.12 |
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| SRR23303752 | — | 0.825 |
| EPT0291 | EPN | 0.820 |
| aMVAC.P_005_TURBT_S223 | — | 0.810 |
| SRR10899984 | — | 0.807 |
| C3N-03420 | — | 0.800 |
Annotations
Sign in to read and post annotations.
Loading…